To include your compound in the COVID-19 Resource Center, submit it here.

Genzyme deal

By WIR Staff | Nov 7, 1994 | 8:00 AM GMT

The Cambridge, Mass., company licensed retroviral vector technology

Read the full 81 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE